Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859262 | 0.77 | CA12 (0.42) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL8172237 | 0.77 | CA12 (0.42) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL965921 | 0.74 | — | — | |
| SCHEMBL3833150 | 0.74 | — | — | |
| SCHEMBL28312106 | 0.70 | CA12 (0.37) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL1563095 | 0.69 | — | — | |
| SCHEMBL965717 | 0.69 | — | — | |
| SCHEMBL24462 | 0.67 | — | — | |
| SCHEMBL9878380 | 0.67 | ALDH1A1 (0.48) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL3073891 | 0.65 | CA12 (0.48) | CA12CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491951-B1 | BLOCK COPOLYMER FOR INTRAPERITONEAL ADMINISTRATION CONTAINING ANTI-CANCER AGENT, MICELLE PREPARATION, AND CANCER THERAPEUTIC AGENT COMPRISING THE MICELLE PREPARATION AS ACTIVE INGREDIENT | NIPPON KAYAKU KK (JP) | 2017-09-20 | — | — | EP | claimed |
| US-20160279164-A1 | High-Molecular Weight Conjugate Of Resorcinol Derivatives | NIPPON KAYAKU KK (JP) | 2016-09-29 | — | — | US | claimed |
| EP-2070971-B1 | COMPOUND OF RESORCINOL DERIVATIVE WITH POLYMER | NIPPON KAYAKU KK (JP) | 2016-06-22 | — | — | EP | claimed |
| EP-2080779-B1 | POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST | NIPPON KAYAKU KK (JP) | 2016-05-18 | — | — | EP | claimed |
| EP-2090607-B1 | POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST | NIPPON KAYAKU KK (JP) | 2015-05-20 | — | — | EP | claimed |
| US-20150011715-A1 | High-Molecular Weight Conjugate Of Resorcinol Derivatives | NIPPON KAYAKU KK (JP) | 2015-01-08 | — | — | US | claimed |
| EP-1580216-B1 | HIGH-MOLECULAR WEIGHT DERIVATIVES OF CAMPTOTHECINS | NIPPON KAYAKU KK (JP) | 2014-05-14 | — | — | EP | claimed |
| US-20140072604-A1 | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2014-03-13 | — | — | US | claimed |
| US-8334364-B2 | High-molecular weight derivative of nucleic acid antimetabolite | NIPON KAYAKU KABUSHIKI KAISHA (JP) | 2012-12-18 | — | — | US | claimed |
| US-20120231053-A1 | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2012-09-13 | — | — | US | claimed |
| US-8188222-B2 | High molecular weight derivative of nucleic acid antimetabolite | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2012-05-29 | — | — | US | claimed |
| US-20100029849-A1 | HIGH MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-02-04 | — | — | US | claimed |
| US-20090281300-A1 | HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-11-12 | — | — | US | claimed |
| US-20090239782-A1 | High-molecular weight conjugate of resorcinol derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-09-24 | — | — | US | claimed |
| EP-2090607-A1 | POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST | Nippon Kayaku Kabushiki Kaisha (JP) | 2009-08-19 | — | — | EP | claimed |
| EP-2080779-A1 | POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST | Nippon Kayaku Kabushiki Kaisha (JP) | 2009-07-22 | — | — | EP | claimed |
| EP-2070971-A1 | COMPOUND OF RESORCINOL DERIVATIVE WITH POLYMER | Nippon Kayaku Kabushiki Kaisha (JP) | 2009-06-17 | — | — | EP | claimed |
| US-7495099-B2 | High-molecular weight derivatives of camptothecins | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | claimed |
| US-20060067910-A1 | High-molecular weight derivatives of camptothecins | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-03-30 | — | — | US | claimed |
| EP-1580216-A1 | HIGH-MOLECULAR WEIGHT DERIVATIVES OF CAMPTOTHECINS | Nippon Kayaku Kabushiki Kaisha (JP) | 2005-09-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281300-A1 | HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE | POLRMT, POLN, POLI | CA12 1124/4885CA1 1957/4885CA2 2542/4885 |
| US-20140072604-A1 | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient | VEGFA, PDAP1, MTDH | CA12 566/4885CA1 301/4885CA2 2597/4885 |
| US-20090239782-A1 | High-molecular weight conjugate of resorcinol derivatives | WDR48, SLC43A1, LRAT | CA12 1520/4885CA1 3281/4885CA2 3738/4885 |
| US-20160279164-A1 | High-Molecular Weight Conjugate Of Resorcinol Derivatives | WDR48, SLC43A1, LRAT | CA12 1520/4885CA1 3281/4885CA2 3738/4885 |
| US-20060067910-A1 | High-molecular weight derivatives of camptothecins | PCNA, ACP1, PDAP1 | CA12 1104/4885CA1 1290/4885CA2 1792/4885 |
| US-20120231053-A1 | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient | VEGFA, PDAP1, MTDH | CA12 566/4885CA1 301/4885CA2 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.